These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 15471507

  • 21. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study).
    Dinger JC, Bardenheuer K, Assmann A.
    BMC Med Res Methodol; 2009 Nov 18; 9():77. PubMed ID: 19922634
    [Abstract] [Full Text] [Related]

  • 22. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS, Kaye JA, Russmann S, Jick H.
    Contraception; 2006 Jun 18; 73(6):566-70. PubMed ID: 16730485
    [Abstract] [Full Text] [Related]

  • 23. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP, Goldzieher JW.
    J Reprod Med; 2003 Nov 18; 48(11 Suppl):930-8. PubMed ID: 14686030
    [Abstract] [Full Text] [Related]

  • 24. Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel.
    Regidor PA, Colli E, Palacios S.
    Gynecol Endocrinol; 2021 Dec 18; 37(12):1121-1127. PubMed ID: 34402728
    [Abstract] [Full Text] [Related]

  • 25. Yasmin: the reason why.
    Thorneycroft IH.
    Eur J Contracept Reprod Health Care; 2002 Dec 18; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [Abstract] [Full Text] [Related]

  • 26. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
    Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A.
    Eur J Contracept Reprod Health Care; 2015 Dec 18; 20(5):329-43. PubMed ID: 26007631
    [Abstract] [Full Text] [Related]

  • 27. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr 18; 7(1):3-6. PubMed ID: 12320047
    [Abstract] [Full Text] [Related]

  • 28. Drospirenone- and levonorgestrel-containing oral contraceptives and the risk of gallbladder disease.
    Jick S, Pennap D.
    Contraception; 2012 Sep 18; 86(3):220-3. PubMed ID: 22325114
    [Abstract] [Full Text] [Related]

  • 29. The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs.
    McAdams M, Staffa JA, Dal Pan GJ.
    Contraception; 2007 Oct 18; 76(4):278-81. PubMed ID: 17900437
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L, Buhling KJ, Rybowski S, Roth K, Rosen K.
    Eur J Contracept Reprod Health Care; 2016 Oct 18; 21(5):372-9. PubMed ID: 27494570
    [Abstract] [Full Text] [Related]

  • 32. Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
    Adeyanju OA, Olatunji LA.
    J Basic Clin Physiol Pharmacol; 2019 Aug 30; 30(5):. PubMed ID: 31469652
    [Abstract] [Full Text] [Related]

  • 33. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
    Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM.
    Contraception; 2021 Apr 30; 103(4):213-221. PubMed ID: 33428907
    [Abstract] [Full Text] [Related]

  • 34. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H, Foidart JM, Heithecker R.
    Eur J Contracept Reprod Health Care; 2001 Sep 30; 6(3):167-71. PubMed ID: 11763981
    [Abstract] [Full Text] [Related]

  • 35. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA, Dinger JC, Assmann A, Minh TD.
    Contraception; 2010 May 30; 81(5):401-7. PubMed ID: 20399946
    [Abstract] [Full Text] [Related]

  • 36. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr 30; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 37. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
    Svojanovská K.
    Ceska Gynekol; 2010 Oct 30; 75(5):474-80. PubMed ID: 21374928
    [Abstract] [Full Text] [Related]

  • 38. Risk of venous thromboembolism with drospirenone-containing oral contraceptives.
    Brown DA, Vartan CM.
    Am J Health Syst Pharm; 2011 Jun 01; 68(11):1003-10. PubMed ID: 21593228
    [Abstract] [Full Text] [Related]

  • 39. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
    Reid R, CLINICAL PRACTICE GYNAECOLOGY COMMITTEE.
    J Obstet Gynaecol Can; 2010 Dec 01; 32(12):1192-1197. PubMed ID: 21176332
    [Abstract] [Full Text] [Related]

  • 40. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
    Bart S, Marr J, Diefenbach K, Trummer D, Sampson-Landers C.
    Contraception; 2012 Jan 01; 85(1):42-50. PubMed ID: 22067790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.